Head to Head Survey: Curaleaf (CURLF) and The Competition

Curaleaf (OTCMKTS:CURLFGet Rating) is one of 57 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it compare to its rivals? We will compare Curaleaf to similar businesses based on the strength of its profitability, institutional ownership, earnings, dividends, valuation, risk and analyst recommendations.

Institutional & Insider Ownership

14.5% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 28.4% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Curaleaf and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curaleaf 0 1 7 0 2.88
Curaleaf Competitors 190 527 725 41 2.42

Curaleaf currently has a consensus target price of $12.25, suggesting a potential upside of 87.31%. As a group, “Medicinals & botanicals” companies have a potential upside of 171.39%. Given Curaleaf’s rivals higher probable upside, analysts clearly believe Curaleaf has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Curaleaf and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Curaleaf $1.21 billion -$101.73 million -36.33
Curaleaf Competitors $265.37 million -$99.14 million -10.80

Curaleaf has higher revenue, but lower earnings than its rivals. Curaleaf is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Curaleaf and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Curaleaf -9.72% -7.08% -3.70%
Curaleaf Competitors 435.50% -64.31% 103.46%


Curaleaf rivals beat Curaleaf on 8 of the 12 factors compared.

About Curaleaf

(Get Rating)

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back-office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers flowers, pre-rolls, flower pods, and dry-herb vaporizer cartridges; concentrates for vaporizing, such as pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, including distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. The company also provides hemp-based CBD products. As of June 16, 2022, it operated 134 dispensaries and 26 cultivation sites in 22 states of the United States. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.

Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.